Dendritic Cell (DC) Therapy + Leukapheresis for Cancer Treatment | Practice Group for Cell Therapy in Duderstadt, Germany

Dendritic cell (DC) immunotherapy is a cutting-edge approach in cancer treatment that harnesses the body’s own immune system to target and eliminate cancer cells. Dendritic cells are immune cells that play a pivotal role in the immune response by acting as messengers between the innate and adaptive immune systems. Their primary function is to capture, process, and present antigens to T-cells, thereby activating a targeted immune response. In cancer, these cells can be used therapeutically to stimulate the immune system to recognize and attack cancer cells more effectively. The process of dendritic cell immunotherapy begins by isolating dendritic cells from the patient’s blood. These cells are then exposed to tumor-associated antigens in the laboratory. Tumor antigens are proteins or molecules that are expressed on the surface of cancer cells, but not on normal cells. By exposing dendritic cells to these antigens, they become activated and "educated" to recognize the specific cancer cells that harbor them. Once the dendritic cells have been prepared, they are reintroduced into the patient’s body via infusion, where they travel to lymph nodes and other immune system sites to present tumor antigens to T cells. This process leads to the activation of T-cells, which can then seek out and destroy cancer cells that express those specific antigens. One of the major benefits of DC immunotherapy is its ability to provide highly targeted treatment with minimal damage to surrounding healthy tissues. Unlike traditional cancer therapies, such as chemotherapy and radiation, which can cause widespread damage to healthy cells, DC immunotherapy enhances the body's natural immune response against cancer without the same level of toxicity. Additionally, this treatment can help generate long-lasting immune memory, allowing the body to recognize and respond to cancer cells if they recur. This immunological "memory" can provide a lasting protective effect, potentially preventing cancer from coming back. The dendritic cells are generated from the patient’s monocytes, which will be harvested by leukapheresis, using a standard cytokine cocktail in a GMP-certified lab. On day 7, the dendritic cells are harvested in physiological salt solution for intradermal application. For each vaccine preparation, the quality of the dendritic cells is assessed by measuring characteristic surface markers using flow cytometry, performing microscopic controls, and performing standard sterility tests. This process is typically repeated multiple times over a set period to reinforce the immune system's ability to fight cancer. The number of treatments and the duration of therapy can vary depending on the type of cancer and the patient’s individual response to the therapy. One of the key advantages of DC immunotherapy is its personalization. Since the treatment is derived from the patient's own immune cells, it is highly specific to the individual’s cancer. The therapeutic approach is tailored to the patient’s unique tumor profile, resulting in more effective and precise treatment. Additionally, as the therapy stimulates the patient’s immune system to recognize and attack cancer cells, it can be combined with other cancer treatments, such as chemotherapy, radiation, and surgery, to enhance their efficacy. There are ongoing studies and clinical trials investigating the effectiveness of dendritic cell immunotherapy in treating various types of cancer, including melanoma, prostate cancer, lung cancer, breast cancer, and glioblastoma. Research has shown promising results in certain cancers, particularly when traditional treatments have not been fully successful. However, as with any emerging treatment, the effectiveness of DC immunotherapy can vary from patient to patient, and more research is needed to fully understand its potential in cancer therapy. While dendritic cell immunotherapy generally has fewer side effects compared to conventional cancer treatments, it is not without risks. Some patients may experience mild side effects, such as flu-like symptoms (fever, chills, and fatigue), following the infusion. These symptoms are typically a result of the immune system being activated and usually subside after a few days. Serious side effects are rare but can include an allergic reaction or infusion-related issues. It is important for patients undergoing dendritic cell immunotherapy to be closely monitored by their healthcare team during treatment to ensure safety and address any potential issues promptly. In summary, dendritic cell immunotherapy represents an innovative and personalized approach to cancer treatment. By harnessing the patient’s immune system and targeting the specific antigens on cancer cells, this therapy aims to provide a more targeted, less toxic alternative to traditional treatments. As research continues to evolve, dendritic cell immunotherapy holds the promise of becoming a key component of cancer treatment, particularly for patients with difficult-to-treat cancers or those seeking alternatives to more conventional therapies.